John Sarantopoulos

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 433 citations

Second-line Treatment, Oncology, Metronomic Therapy +9

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Clinical Cancer Research · 2021 · 335 citations · Full text

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

Anthony W. Tolcher, John Sarantopoulos, Amita Patnaik et al. · Journal of Clinical Oncology · 2009 · 307 citations

Combined autophagy and HDAC inhibition

Devalingam Mahalingam, Monica Mita, John Sarantopoulos et al. · Autophagy · 2014 · 281 citations · Full text

Mitophagy, Chemoprevention Strategy, Immunology +18

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text